Daniel C Christoph1, Wilfried E E Eberhardt. 1. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, North Rhine-Westphalia, Germany.
Abstract
PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a rare malignancy with limited therapeutic options and its incidence is still increasing in both Europe and the developing nations. Prognosis of MPM patients is poor even if the median survival durations have been slightly improved after the introduction of the up-to-date chemotherapy combination with pemetrexed and cisplatin. There is a continuing unmet need to develop better systemic treatment for this disease, but the rarity of the tumor type creates formidable challenges in clinical trial research. RECENT FINDINGS: Better understanding of the molecular machinery of MPM leads to the design and synthesis of novel compounds targeted against pathways identified as crucial for MPM cell proliferation and metastasis. Most efforts aim at improving standard first-line therapy, or developing effective second-line treatments. Several classes of drugs are currently being explored either in combination with cisplatin and pemetrexed or as single agent for relapsed or progressive MPM. SUMMARY: This review focuses on several ongoing or recently completed clinical trials investigating novel, promising agents as first-line or second-line therapy for advanced MPM.
PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a rare malignancy with limited therapeutic options and its incidence is still increasing in both Europe and the developing nations. Prognosis of MPM patients is poor even if the median survival durations have been slightly improved after the introduction of the up-to-date chemotherapy combination with pemetrexed and cisplatin. There is a continuing unmet need to develop better systemic treatment for this disease, but the rarity of the tumor type creates formidable challenges in clinical trial research. RECENT FINDINGS: Better understanding of the molecular machinery of MPM leads to the design and synthesis of novel compounds targeted against pathways identified as crucial for MPM cell proliferation and metastasis. Most efforts aim at improving standard first-line therapy, or developing effective second-line treatments. Several classes of drugs are currently being explored either in combination with cisplatin and pemetrexed or as single agent for relapsed or progressive MPM. SUMMARY: This review focuses on several ongoing or recently completed clinical trials investigating novel, promising agents as first-line or second-line therapy for advanced MPM.
Authors: Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri Journal: Nat Genet Date: 2016-02-29 Impact factor: 38.330
Authors: Mahadev Rao; Scott M Atay; Vivek Shukla; Young Hong; Trevor Upham; R Taylor Ripley; Julie A Hong; Mary Zhang; Emily Reardon; Patricia Fetsch; Markku Miettinen; Xinmin Li; Cody J Peer; Tristan Sissung; William D Figg; Assunta De Rienzo; Raphael Bueno; David S Schrump Journal: Clin Cancer Res Date: 2015-10-12 Impact factor: 12.531
Authors: Francesca Amoroso; Erica Salaro; Simonetta Falzoni; Paola Chiozzi; Anna Lisa Giuliani; Giorgio Cavallesco; Pio Maniscalco; Andrea Puozzo; Ilaria Bononi; Fernanda Martini; Mauro Tognon; Francesco Di Virgilio Journal: Oncotarget Date: 2016-08-02
Authors: Robert Fred Henry Walter; Saskia Roxanne Sydow; Erika Berg; Jens Kollmeier; Daniel Christian Christoph; Sandra Christoph; Wilfried Ernst Erich Eberhardt; Thomas Mairinger; Jeremias Wohlschlaeger; Kurt Werner Schmid; Fabian Dominik Mairinger Journal: Cancer Manag Res Date: 2019-09-24 Impact factor: 3.989
Authors: Sabrina Borchert; Michael Wessolly; Jan Schmeller; Elena Mairinger; Jens Kollmeier; Thomas Hager; Thomas Mairinger; Thomas Herold; Daniel C Christoph; Robert F H Walter; Wilfried E E Eberhardt; Till Plönes; Jeremias Wohlschlaeger; Clemens Aigner; Kurt Werner Schmid; Fabian D Mairinger Journal: BMC Cancer Date: 2019-01-30 Impact factor: 4.430
Authors: Moshe Lapidot; Abigail E Case; Ellen L Weisberg; Chengcheng Meng; Sarah R Walker; Swati Garg; Wei Ni; Klaus Podar; Yin P Hung; Ruben D Carrasco; Aine Knott; Prafulla C Gokhale; Sunil Sharma; Alex Pozhitkov; Prakash Kulkarni; David A Frank; Ravi Salgia; James D Griffin; Srinivas V Saladi; Raphael Bueno; Martin Sattler Journal: Br J Cancer Date: 2021-06-04 Impact factor: 7.640